| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
L-Lysine-13C6,15N2 HCl targets the same biological pathways as unlabeled L-lysine, an essential amino acid that serves as a building block for protein synthesis. L-lysine is involved in various physiological processes including calcium absorption, collagen formation, and immune function. The labeled compound is primarily used as a tracer in mass spectrometry and metabolic studies rather than for therapeutic targeting. It allows for the quantification and tracking of lysine metabolism in cells and tissues.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
L-Lysine-13C6,15N2 HCl is a stable isotope-labeled amino acid used as a tracer in mass spectrometry studies. L-lysine, the unlabeled parent compound, is an essential amino acid involved in protein synthesis, calcium absorption, and immune function. The labeled compound allows for the tracking of lysine metabolism and protein turnover in cells. It has been used in pSILAC (pulsed stable isotope labeling by amino acids in cell culture) mass spectrometry to study protein profiles in cells transfected with microRNAs. |
| ln Vivo |
In vivo, L-lysine is an essential amino acid that is absorbed from the diet and incorporated into proteins. L-Lysine-13C6,15N2 HCl can be administered to animals or humans as a tracer to study lysine metabolism and protein turnover. The labeled compound is detected by mass spectrometry, allowing for the quantification of lysine flux in various tissues. Specific in vivo efficacy studies for the labeled compound are not applicable, as it is used as an analytical tracer rather than a therapeutic agent.
|
| Enzyme Assay |
In vitro assays for L-Lysine-13C6,15N2 HCl typically involve its use as an internal standard or tracer in mass spectrometry-based metabolic studies. The compound is added to cell culture media or biological samples at known concentrations. Samples are analyzed by LC-MS/MS or GC-MS to quantify lysine and its metabolites. The labeled compound allows for accurate quantification and tracking of lysine metabolism. Standard protocols involve protein precipitation, derivatization (for GC-MS), and mass spectrometric analysis.
|
| Cell Assay |
In vitro cellular assays for L-Lysine-13C6,15N2 HCl typically involve culturing cells in media containing the labeled amino acid. Cells are incubated with the labeled lysine for various time periods (typically 1-72 hours) to allow for incorporation into proteins. Protein extracts are prepared and analyzed by mass spectrometry to quantify protein synthesis and turnover rates. The labeled compound allows for the tracking of newly synthesized proteins and the study of protein dynamics.
|
| Animal Protocol |
In vivo animal studies for L-Lysine-13C6,15N2 HCl typically involve administering the labeled compound to mice or rats via oral gavage, intravenous injection, or dietary supplementation. Blood, urine, and tissue samples are collected at various time points and analyzed by mass spectrometry to track lysine metabolism and protein turnover. The labeled compound allows for the quantification of lysine flux and protein synthesis rates in different tissues. Doses are determined based on the specific study objectives.
|
| ADME/Pharmacokinetics |
L-Lysine-13C6,15N2 HCl has a molecular weight of 190.59 g/mol and formula 13C6H1515N2O2·HCl. The compound has a melting point of 263-264°C (dec.) and a purity of 95%. It is soluble in water and is typically stored at -20°C. The compound is stable under recommended storage conditions. Detailed PK parameters would be similar to those of unlabeled L-lysine, which is actively transported and metabolized in the body.
|
| Toxicity/Toxicokinetics |
Toxicity data for L-Lysine-13C6,15N2 HCl are similar to those of unlabeled L-lysine, which is an essential amino acid with low toxicity. L-lysine is generally recognized as safe when consumed as a dietary supplement. The labeled compound is intended for research use only and is not approved for human therapeutic applications. Standard safety precautions should be taken when handling the compound.
|
| References |
|
| Additional Infomation |
L-Lysine-13C6,15N2 HCl (CAS 1200447-00-2) is a stable isotope-labeled form of L-lysine hydrochloride. It has a molecular weight of 190.59 g/mol and formula 13C6H1515N2O2·HCl. The compound is used as a tracer in mass spectrometry and metabolic studies. L-lysine is an essential amino acid with multiple health benefits. The labeled compound has been used in pSILAC mass spectrometry to study protein profiles. It is also known as (S)-2,6-diaminohexanoic acid-13C6,15N2 hydrochloride. The compound is not approved for clinical use.
|
| Exact Mass |
190.096
|
|---|---|
| CAS # |
1200447-00-2
|
| Related CAS # |
L-Lysine hydrochloride;657-27-2
|
| PubChem CID |
71310242
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
>210°C (dec.)(lit.)
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
11
|
| Complexity |
106
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[13CH2]([13CH2][13CH2][15NH2])[13CH2][13C@@H]([13C](=O)O)[15NH2].Cl
|
| InChi Key |
BVHLGVCQOALMSV-GSMNGUNQSA-N
|
| InChi Code |
InChI=1S/C6H14N2O2.ClH/c7-4-2-1-3-5(8)6(9)10;/h5H,1-4,7-8H2,(H,9,10);1H/t5-;/m0./s1/i1+1,2+1,3+1,4+1,5+1,6+1,7+1,8+1;
|
| Chemical Name |
(2S)-2,6-bis(15N)(azanyl)(1,2,3,4,5,6-13C6)hexanoic acid;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~250 mg/mL (~1311.72 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
